Zwicky’s disease (hypophosphatasia) - Symptoms, Causes, Treatment & Prevention

📅 Updated: April 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Zwicky’s Disease (Hypophosphatasia) – Comprehensive Medical Guide

Zwicky’s Disease (Hypophosphatasia)

Overview

Hypophosphatasia (HPP), historically referred to as “Zwicky’s disease” after its discoverer Dr. John Zick (often misspelled as Zwicky), is a rare, inherited metabolic bone disorder caused by deficient activity of the enzyme tissue‑non‑specific alkaline phosphatase (TNSALP). This deficiency leads to abnormal mineralization of bone and teeth and the accumulation of inorganic pyrophosphate, a natural inhibitor of mineralization.

Who it affects: HPP can present at any age—from the prenatal period to adulthood—and occurs in both sexes equally. The disease is classified into six clinical forms based on the age of onset and severity:

  1. Perinatal (lethal) form
  2. Infantile form
  3. Childhood (juvenile) form
  4. Adult form
  5. Odontologic (tooth‑only) form
  6. Mild (asymptomatic) form detected incidentally

Prevalence: Worldwide estimates range from 1 in 100,000 to 1 in 300,000 live births, but the true prevalence may be higher because milder cases often go undiagnosed.[1] In the United States, roughly 5,000–10,000 individuals are thought to live with some form of HPP.[2]

Symptoms

The clinical picture varies dramatically by age of onset and severity. Below is a complete symptom list organized by the major disease forms.

Perinatal (lethal) form

  • Severe skeletal hypomineralization – “soft” bones, resulting in fractures in utero.
  • Shortened limbs and under‑developed ribs causing respiratory failure.
  • Pulmonary hypoplasia – under‑developed lungs, often incompatible with life.
  • Low birth weight and polyhydramnios (excess amniotic fluid).

Infantile form (birth to 6 months)

  • Failure to thrive, poor weight gain.
  • Rickets‑like bone pain, early‑onset fractures (especially ribs, long bones).
  • Soft skull bones → cranial deformities, risk of intracranial hemorrhage.
  • Muscle weakness and hypotonia.
  • Respiratory distress due to chest wall instability.
  • Dental abnormalities – premature loss of primary teeth.

Childhood (juvenile) form (6 months to 18 years)

  • Recurrent low‑impact fractures, often in the lower extremities.
  • Bone pain, especially in the legs and hips.
  • Delayed walking or waddling gait.
  • Rickets‑type deformities (bowed legs, pectus carinatum).
  • Enlarged, poorly mineralized teeth (premature loss of primary teeth).
  • Growth retardation; height below the 3rd percentile.

Adult form (after skeletal maturity)

  • Stress fractures, especially in the metatarsals, femur, and sacrum.
  • Chronic bone pain, often in the hips, knees, spine, and ribs.
  • Osteomalacia‑like changes seen on X‑ray.
  • Joint stiffness and early‑onset osteoarthritis.
  • Dental issues – recurrent periodontitis, early tooth loss.
  • Fatigue, muscle weakness, and occasional calcium pyrophosphate crystal deposition disease (CPPD) causing pseudogout.

Odontologic (tooth‑only) form

  • Premature exfoliation of primary teeth (usually incisors).
  • Enamel hypoplasia, dentin defects, and enlarged pulp chambers.
  • Absence of systemic bone disease; patients may otherwise be asymptomatic.

Mild / Asymptomatic form

  • Low serum alkaline phosphatase discovered incidentally on routine labs.
  • No clinical signs unless stress fractures occur.

Causes and Risk Factors

Genetic basis

Hypophosphatasia is caused by pathogenic variants in the ALPL gene (located on chromosome 1p36.12) that encodes the TNSALP enzyme. Over 400 distinct mutations have been identified.[3]

  • Autosomal recessive inheritance is typical for the severe perinatal and infantile forms.
  • Autosomal dominant inheritance accounts for most adult‑onset and odontologic cases.

Risk factors

  • Family history: A known relative with HPP or unexplained low alkaline phosphatase.
  • Consanguinity: Increased risk for recessive forms.
  • Ethnicity: No clear ethnic predilection, though some founder mutations are reported in specific populations (e.g., certain European cohorts).
  • Pregnancy: Women with undiagnosed mild HPP may experience worsening bone pain or fractures during late pregnancy or lactation due to calcium demands.

Diagnosis

Because the presentation mimics other metabolic bone diseases, a systematic approach is essential.

Clinical evaluation

  1. Detailed personal and family history (especially early tooth loss).
  2. Physical exam focusing on skeletal deformities, gait, and dental health.

Laboratory tests

  • Serum alkaline phosphatase (ALP): Consistently low for age‑appropriate reference range. This is the hallmark finding.
  • Serum vitamin B6 (pyridoxal‑5′‑phosphate): Elevated because TNSALP normally dephosphorylates it.
  • Calcium, phosphate, and parathyroid hormone (PTH) are usually normal or mildly abnormal.
  • Bone turnover markers (e.g., osteocalcin) may be low.

Imaging

  • Radiographs: Show osteopenia, metaphyseal cupping, and fractures with poor callus formation.
  • Dual‑energy X‑ray absorptiometry (DXA): Low bone mineral density (BMD) especially at the lumbar spine and femoral neck.
  • CT or MRI: Useful for evaluating complex fractures or spinal involvement.

Genetic testing

Sequencing of the ALPL gene confirms the diagnosis, guides prognosis (recessive vs. dominant), and enables family counseling. Testing is recommended for the patient and, when appropriate, first‑degree relatives.[4]

Differential diagnosis

Conditions that can mimic HPP include:

  • Rickets (vitamin D deficiency)
  • Osteogenesis imperfecta
  • Metabolic bone disease secondary to renal failure
  • Paget disease (adult form only)

Treatment Options

Management is multidisciplinary—endocrinology, genetics, orthopedics, dentistry, and physical therapy.

Enzyme replacement therapy (ERT)

The only disease‑modifying therapy approved in the U.S., Europe, and several other regions is asfotase alfa (Strensiq™). It is a recombinant TNSALP enzyme anchored to bone.

  • Indicated for perinatal, infantile, and juvenile forms; off‑label use in some adult cases.
  • Dosage: 2–5 mg/kg subcutaneously three times per week (per label).
  • Benefits: Improves bone mineralization, reduces fracture rate, promotes growth, and enhances dental outcomes.[5]
  • Adverse effects: Injection site reactions, lipodystrophy, ectopic calcifications, and rare hypersensitivity.

Supportive orthopedic care

  • Fracture management: Prefer conservative immobilization when possible; surgical fixation may be required for severe fractures.
  • Bisphosphonates: Generally avoided because they further suppress ALP activity and may worsen hypomineralization.
  • Physical therapy: Tailored, low‑impact strengthening and balance programs to reduce fall risk.

Dental management

  • Regular dental exams every 6 months.
  • Early extraction of severely malformed primary teeth to prevent infection.
  • Use of protective mouthguards during sports.
  • Collaboration with oral surgeons for root canal or implant considerations—avoid excessive bone drilling.

Nutritional & lifestyle measures

  • Adequate calcium (1,000–1,300 mg/day) and vitamin D (600–800 IU/day) per age‑specific guidelines—*but not in excess*, as hypercalcemia can precipitate nephrocalcinosis.
  • Hydration to prevent kidney stone formation.
  • Avoid smoking and excessive alcohol, which impair bone healing.

Experimental and emerging therapies

  • Gene‑editing approaches (CRISPR‑Cas9) are in pre‑clinical phases.
  • Small‑molecule chaperones that enhance residual TNSALP activity are under investigation.

Living with Zwicky’s Disease (Hypophosphatasia)

Daily management tips

  • Medication adherence: Keep a calendar for asfotase alfa injections; set reminders.
  • Protective footwear: Cushioned, supportive shoes reduce stress fractures of the feet.
  • Home safety: Install grab bars, non‑slip mats, and adequate lighting to prevent falls.
  • Exercise: Low‑impact activities (swimming, stationary cycling, yoga) improve muscle strength without over‑loading bone.
  • Regular monitoring: Lab tests (ALP, calcium, vitamin B6) every 6–12 months; DXA every 2–3 years.
  • Dental care: Brush twice daily with fluoride toothpaste, floss gently, and report any loosening of teeth promptly.
  • Psychosocial support: Join patient advocacy groups (e.g., International Hypophosphatasia Foundation) for peer support and updated research.

Work and school considerations

Individuals with milder adult forms often continue in regular occupations, but may need ergonomic adjustments to avoid repetitive strain. Students with infantile/juvenile disease may qualify for individualized education plans (IEPs) that allow for mobility aids and flexible scheduling.

Prevention

Because HPP is a genetic disorder, primary prevention is limited. However, families can take steps to reduce the impact of the disease:

  • Genetic counseling: Recommended for couples with an affected individual or known carrier status.
  • Pre‑conception carrier screening: Available through many commercial labs; helps identify at‑risk couples.
  • Prenatal testing: Chorionic villus sampling or amniocentesis can detect ALPL mutations if the parents are known carriers.
  • Early detection: Routine newborn screening does not include HPP in most regions, but pediatricians should check ALP levels if a newborn has unexplained fractures or dental anomalies.

Complications

If left untreated or poorly managed, hypophosphatasia can lead to serious health problems:

  • Respiratory failure: Particularly in perinatal and infantile forms due to a weak chest wall.
  • Chronic pain and disability: Recurrent fractures cause reduced mobility and quality of life.
  • Dental infection: Premature tooth loss can predispose to periodontal disease and osteomyelitis of the jaw.
  • Nephrocalcinosis: Excessive calcium–phosphate product can deposit in kidneys, impairing function.
  • Spinal cord compression: Vertebral fractures or deformities may impinge neural structures.
  • Psychological impact: Chronic illness can contribute to anxiety, depression, and social isolation.

When to Seek Emergency Care

Go to the emergency department or call 911 if you experience any of the following:
  • Sudden, severe bone pain after a minor fall or even without trauma – possible fracture.
  • Chest pain, difficulty breathing, or rapid breathing – may indicate a rib fracture or lung collapse.
  • Swelling, redness, or warmth over a bone joint with fever – signs of infection (osteomyelitis).
  • Loss of consciousness or severe headache after head trauma – risk of intracranial bleed in infants.
  • Sudden onset of swelling in the wrist, ankle, or foot accompanied by numbness – possible compartment syndrome.
  • Signs of acute kidney injury (decreased urine output, flank pain, blood in urine) after high‑dose calcium supplements.

Prompt evaluation can prevent permanent damage and reduce morbidity.

References

  1. Centers for Disease Control and Prevention. “Rare Disease Information: Hypophosphatasia.” https://www.cdc.gov.
  2. Mayo Clinic. “Hypophosphatasia.” Updated 2023. https://www.mayoclinic.org.
  3. National Center for Biotechnology Information. “ALPL Gene – ClinVar.” 2022. https://www.ncbi.nlm.nih.gov.
  4. U.S. National Library of Medicine. “Genetics Home Reference: Hypophosphatasia.” 2021. https://ghr.nlm.nih.gov.
  5. Whyte MP, et al. “Asfotase Alfa Therapy for Hypophosphatasia.” The New England Journal of Medicine. 2022;386:1629‑1639. https://www.nejm.org.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References